RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Tonghua Dongbao Pharma acquired China rights to two diabetes treatments from Adocia of Lyon, France in an agreement worth up to $135 million. Dongbao will have rights to BioChaperone® Combo, a fixed-ratio insulin glargine and insulin lispro combination, plus BioChaperone® Lispro, an ultra-rapid insulin. Adocia’s BioChaperone platform uses polymers, oligomers and small organic compounds to protect proteins from degradation. Dongbao already has a portfolio of diabetes treatments.
Source: China Biotoday
